Keliximab
From Wikipedia, the free encyclopedia
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (primate/human) |
Target | CD4 |
Clinical data | |
Routes of administration |
intravenous |
Identifiers | |
CAS Number | 174722-30-6 ![]() |
ATC code | none |
ChemSpider | none |
![]() ![]() |
Keliximab is a monoclonal antibody for the treatment of severe chronic asthma. It suppresses the immune reaction by binding to white blood cells via the protein CD4.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]
References[edit]
- ^ Kon, OM; Sihra, BS; Compton, CH; Leonard, TB; Kay, AB; Barnes, NC (1998). "Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma". Lancet. 352 (9134): 1109–13. doi:10.1016/S0140-6736(97)12261-9. PMID 9798587.
- ^ WHO Drug Information
![]() |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
![]() |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |